Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study of Demographics, Provider Landscape, and Comorbidities

A.B.C. has served as an investigator for Incyte and AstraZeneca. K.L. has served as an investigator for Novartis. V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt's Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. J.L.H. is on the board of directors for the HS Foundation and has served as an advisor, investigator, and/or speaker for AbbVie, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Novartis, Pfizer, Regeneron, Sanofi, and UCB. The other authors have no conflicts of interest to declare.